Ascentage Pharma presents multiple oncology clinical updates
- Ascentage Pharma delivered 17 distinct operational updates regarding its primary therapeutic pipeline at a major global hematology conference.
- The reported data demonstrated elevated patient response metrics and clear minimal residual disease negativity across several ongoing clinical tracks.
- The evaluations across separate phased trials indicated that both leading drug compounds maintained a generally acceptable toxicological profile.
Ascentage Pharma (NASDAQ:AAPG) presented 17 distinct clinical updates highlighting oncology data for its core therapeutic candidates at the EHA2026 Congress in Copenhagen.
The scientific presentations compiled data regarding the clinical efficacy of olverembatinib and lisaftoclax in treating multiple blood cancers, including chronic myeloid leukemia and acute myeloid leukemia.
The shared metrics across Phase Ib–III trials and real-world programs demonstrated high response rates alongside manageable safety boundaries for patients undergoing treatment.
Following the announcement, Ascentage Pharma's share price was up at $17.60.
The company stated that the clinical data sets are expected to advance the strategic development of its small-molecule design platform for global regulatory applications.
The biotechnology firm continues to focus its resources on commercializing targeted therapies to satisfy unaddressed medical demands in international oncology markets.
